CARLSBAD, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Thursday, August 10, 2023 at 9:30 a.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.
A live webcast of the presentation may be accessed by visiting ir.acutusmedical.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days.
About Acutus Medical, Inc.
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.
Investor Contact
Caroline Corner
ICR Westwicke
D: 415-202-5678
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Rhiannon Pickus
442-232-6094
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.04 |
Daily Change: | -0.05 -53.33 |
Daily Volume: | 19,666 |
Market Cap: | US$1.260M |
November 08, 2023 August 07, 2023 May 15, 2023 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load